Success for a new Generation of Basic Therapeutics The Janus-Kinase -Inhibitor Baricitinib in rheumatoid Arthritis

被引：0
|
作者：
Keysser, G. [1 ]
机构：
[1] Univ Klinikum Halle, Klin Innere Med 2, Dept Innere Med, Ernst Grube Str 40, D-06097 Halle, Saale, Germany
来源：
ZEITSCHRIFT FUR RHEUMATOLOGIE | 2017年 / 76卷 / 05期
关键词：
D O I：
10.1007/s00393-017-0307-3
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
[No abstract available]
引用
收藏
页码：461 / 462
页数：2
相关论文
共 50 条
  • [41] Baricitinib, an Oral Janus Kinase Inhibitor, in the Treatment of Rheumatoid Arthritis: 52 Week Safety and Efficacy in an Open-Label, Long-Term Extension Study
    Baker, Milton
    Chalabi, Youb
    Genovese, Mark
    Taylor, Peter
    Schlichting, Douglas
    Beattie, Scott
    Macias, William
    Keystone, Edward
    JOURNAL OF RHEUMATOLOGY, 2014, 41 (07) : 1505 - 1505
  • [42] Improvement of cutaneous inflammation and panniculitis in patients with dermatomyositis by the Janus kinase inhibitor baricitinib
    Fischer, Kristina
    Aringer, Martin
    Steininger, Julian
    Heil, Julius
    Beissert, Stefan
    Abraham, Susanne
    Gunther, Claudia
    BRITISH JOURNAL OF DERMATOLOGY, 2022, 187 (03) : 432 - 435
  • [43] DFT study on the structural and chemical properties of Janus kinase inhibitor drug Baricitinib
    Sonia, Chiging
    Devi, Th. Gomti
    Karlo, T.
    MATERIALS TODAY-PROCEEDINGS, 2022, 65 : 2586 - 2595
  • [44] Efficacy of Janus kinase 1 and 2 inhibitor baricitinib in multirefractory cutaneous dermatomyositis
    Karaa, S.
    Cassius, C.
    Jachiet, M.
    Mahevas, T.
    Charvet, E.
    Benveniste, O.
    Bouaziz, J. -D.
    ANNALES DE DERMATOLOGIE ET DE VENEREOLOGIE, 2023, 150 (03): : 243 - 245
  • [45] Janus kinase inhibitor baricitinib is not an ideal option for management of COVID-19
    Praveen, D.
    Puvvada, Ranadheer Chowdary
    Aanandhi, Vijey M.
    INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2020, 55 (05)
  • [46] Janus Kinase inhibitor Baricitinib Modulates human innate and adaptive immune system
    Kubo, Satoshi
    Nakayamada, Shingo
    Sakata, Kei
    Kitanaga, Yukihiro
    Ma, Xiaoxue
    Lee, Seunghyun
    Ishii, Akina
    Yamagata, Kaoru
    Nakano, Kazuhisa
    Tanaka, Yoshiya
    FRONTIERS IN IMMUNOLOGY, 2018, 9
  • [47] Increased risk of Pneumocystis jirovecii colonization in rheumatoid arthritis patients on biologics and Janus kinase inhibitor
    Huang, Ya-Chun
    Lee, Nan-Yao
    Weng, Meng-Yu
    JOURNAL OF MICROBIOLOGY IMMUNOLOGY AND INFECTION, 2025, 58 (01) : 112 - 119
  • [48] Developments with investigational Janus kinase inhibitors for rheumatoid arthritis
    Semerano, Luca
    Decker, Patrice
    Clavel, Gaelle
    Boissier, Marie-Christophe
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2016, 25 (12) : 1355 - 1359
  • [49] Treating active rheumatoid arthritis with Janus kinase inhibitors
    Scott, David L.
    Stevenson, Matt D.
    LANCET, 2017, 390 (10093): : 431 - 432
  • [50] Resolution of ocular and mediastinal sarcoidosis after Janus kinase inhibitor therapy for concomitant rheumatoid arthritis
    Sejournet, L.
    Kodjikian, L.
    Grange, L.
    Grumet, P.
    Jamilloux, Y.
    Seve, P.
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2021, 39 (01) : 225 - 226
12345